Barclays Has Lowered Expectations for JAN (NYSE:JAN) Stock Price

JAN (NYSE:JAN) had its price target reduced by research analysts at Barclays from $34.00 to $33.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 14.10% from the stock’s previous close.

A number of other equities analysts have also commented on JAN. Compass Point started coverage on JAN in a research note on Wednesday, September 16th. They issued a “neutral” rating and a $37.00 price objective on the stock. Wall Street Zen upgraded JAN from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. JPMorgan Chase & Co. raised their target price on JAN from $30.00 to $34.00 and gave the company an “overweight” rating in a report on Tuesday, August 18th. Huntington began coverage on JAN in a research report on Thursday, September 10th. They issued an “outperform” rating and a $36.00 price target on the stock. Finally, Zacks Research upgraded JAN from a “hold” rating to a “strong-buy” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, JAN has an average rating of “Moderate Buy” and a consensus price target of $32.38.

JAN Price Performance

Shares of JAN stock traded up $0.19 on Tuesday, reaching $28.92. The stock had a trading volume of 186,235 shares, compared to its average volume of 1,471,221. The business’s 50-day moving average price is $30.14 and its two-hundred day moving average price is $28.00. JAN has a fifty-two week low of $22.76 and a fifty-two week high of $32.83.

JAN (NYSE:JAN) last posted its earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The company had revenue of $216.46 million for the quarter, compared to analyst estimates of $203.32 million. The company’s revenue for the quarter was up 45.4% compared to the same quarter last year. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. On average, sell-side analysts expect that JAN will post 0.97 earnings per share for the current year.

Institutional Trading of JAN

A number of hedge funds have recently modified their holdings of the company. WINTON GROUP Ltd acquired a new stake in shares of JAN during the 2nd quarter worth approximately $2,985,000. Engineers Gate Manager LP bought a new stake in shares of JAN during the second quarter valued at approximately $15,274,000. Greenland Capital Management LP acquired a new position in shares of JAN in the second quarter valued at $575,000. Readystate Asset Management LP bought a new position in JAN in the second quarter worth $1,724,000. Finally, Wellington Management Group LLP bought a new position in JAN in the second quarter worth $8,739,000. Institutional investors own 6.27% of the company’s stock.

JAN News Roundup

Here are the key news stories impacting JAN this week:

• Neutral Sentiment: The AGM announcement is primarily administrative and gives investors an opportunity to engage with management, but it does not disclose new financial results, guidance changes, contracts, or strategic developments likely to materially affect valuation. Janison Sets Hybrid 2026 AGM, Emphasises Shareholder Participation
• Negative Sentiment: Investor attention remains likely to center on Janison’s underlying performance: its latest quarter exceeded revenue expectations and revenue grew strongly year over year, but earnings per share missed consensus estimates. The company’s ability to meet its fiscal 2026 EPS guidance will be more important for the stock than the AGM logistics.

JAN Company Profile

JanOne Inc (NYSE: JAN) is a publicly traded company focused on addressing the opioid crisis through the development and commercialization of solutions intended to improve the treatment and prevention of opioid use disorder. The company has described its mission as combining business, technology and scientific initiatives to help reduce opioid-related harm.

JanOne’s activities have included biotechnology and pharmaceutical-development initiatives, as well as investments in technologies and businesses connected with healthcare and financial services.